Tisagenlecleucel clinical trials
Also written CART-19, CTL019 and KYMRIAH.
How each study uses tisagenlecleucel is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the tisagenlecleucel studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 30 Aug 2017 · Kymriah · BLA 125646 (FDA, Purple Book)
- European Union
- 23 Aug 2018 · Kymriah · EMEA/H/C/004090 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
40 studies that test it; most in 2016 (7)
| Year | Studies |
|---|---|
| 2010 | 2 |
| 2011 | 1 |
| 2013 | 1 |
| 2014 | 4 |
| 2015 | 3 |
| 2016 | 7 |
| 2017 | 2 |
| 2018 | 2 |
| 2019 | 5 |
| 2020 | 3 |
| 2021 | 3 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 16 · Other 24
Novartis Pharmaceuticals (14) · University of Pennsylvania (10) · Memorial Sloan Kettering Cancer Center (1) · Masonic Cancer Center, University of Minnesota (1) · Peter MacCallum Cancer Centre, Australia (1) · Sara V. Latorre (1) · Matthew J. Frigault, M.D. (1) · M.D. Anderson Cancer Center (1)
Often tested with
Tested in the same studies.
Axicabtagene ciloleucel (2) · Fludarabine (2) · Cyclophosphamide (2) · Lisocabtagene maraleucel (2) · Ibrutinib (2) · Brexucabtagene autoleucel (1) · Idecabtagene vicleucel (1) · Mosunetuzumab (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 4, 1 in phase 3
Studies that test tisagenlecleucel, phase 3 first.
- Mar 2027Study of Out of Specification for TisagenlecleucelPhase 3 · Novartis Pharmaceuticals
- Jul 2027A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL)Phase 2 · Memorial Sloan Kettering Cancer Center
- Sep 2027Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell LymphomaPhase 2 · Peter MacCallum Cancer Centre, Australia
- Oct 2027Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive PatientsPhase 2 · Novartis Pharmaceuticals
Studies
Open first, then newest update. How each study uses tisagenlecleucel is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 40
- Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaRecruitingPhase 2SWOG Cancer Research NetworkNCT05633615Written as TisagenlecleucelHow we know
- Lymphodepletion With Low Dose Total Body Irradiation Before Standard of Care Tisagenlecleucel for the Treatment of Relapsed and Recurrent Large B-cell LymphomaRecruitingPhase 1Nathan DenlingerNCT07676877Written as TisagenlecleucelHow we know
- CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for LupusRecruitingPhase 1/2Children's Hospital of PhiladelphiaNCT06839976Written as CART19How we know
- Study of Out of Specification for TisagenlecleucelRecruitingPhase 3Novartis PharmaceuticalsNCT04094311Written as CTL019How we know
- CD19-directed CAR-T Cell Therapy for R/R Acute Leukemia and LymphomaRecruitingPhase 1/2University of Sao PauloNCT06101381Written as CART-19How we know
- CART-19 T Cell in CD19 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)RecruitingPhase 1/2Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdNCT03896854Written as CART-19How we know
- Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive PatientsActive, not recruitingPhase 2Novartis PharmaceuticalsNCT03876769Written as CTL019How we know
- Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular LymphomaCompletedPhase 2Novartis PharmaceuticalsNCT03568461Written as tisagenlecleucelHow we know
- A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular LymphomaActive, not recruitingPhase 3Novartis PharmaceuticalsNCT05888493Written as TisagenlecleucelHow we know
- A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL)Active, not recruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT05460533Written as TisagenlecleucelHow we know
- MT2017-45: CAR-T Cell Therapy for Heme MalignanciesActive, not recruitingPhase 2Masonic Cancer Center, University of MinnesotaNCT03642626Written as KYMRIAHHow we know
- Tisagenlecleucel In Primary CNS LymphomaCompletedPhase 1Matthew J. Frigault, M.D.NCT04134117Written as TisagenlecleucelHow we know
- Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell LymphomaActive, not recruitingPhase 2Peter MacCallum Cancer Centre, AustraliaNCT04234061Written as ibrutinib and TisagenlecleucelHow we know
- Study of the Infusion of ARI-0001 Cells in Patients With CD19 + Acute Lymphoid Leukemia Resistant or Refractory to TherapyActive, not recruitingPhase 2Sara V. LatorreNCT04778579Written as ARI-0001 cellsHow we know
- Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma PatientsCompletedPhase 2Novartis PharmaceuticalsNCT03610724Written as TisagenlecleucelHow we know
- Study of Efficacy and Safety of CTL019 in Adult DLBCL PatientsCompletedPhase 2Novartis PharmaceuticalsNCT02445248Written as TisagenlecleucelHow we know
- Study of Efficacy and Safety of CTL019 in Pediatric ALL PatientsCompletedPhase 2Novartis PharmaceuticalsNCT02435849Written as CTL019How we know
- CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to ChemotherapyCompletedPhase 1University of PennsylvaniaNCT01029366Written as CART-19How we know
- Dose Optimization Trial of CD19 Redirected Autologous T CellsCompletedPhase 2University of PennsylvaniaNCT01747486Written as CART-19How we know
- Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ LymphomasCompletedPhase 2University of PennsylvaniaNCT02030834Written as CART-19How we know
See all 40 studies that test tisagenlecleucel →
Given beside what is tested · 5 — tisagenlecleucel is usual care or a partner of the new treatment
- Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell MalignanciesRecruitingPhase 1Stanford UniversityNCT06408194Written as TisagenlecleucelHow we know
- Ph I/II Study of E7777 Prior to CAR-T for R/R LBCLSuspendedPhase 1/2Masonic Cancer Center, University of MinnesotaNCT04855253Written as TisagenlecleucelHow we know
- Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell TherapyCompletedPhase 1NeoImmuneTechNCT05075603Written as TisagenlecleucelHow we know
- Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS StudyCompletedEarly Phase 1Emory UniversityNCT04890236Written as TisagenlecleucelHow we know
- Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma PatientsCompletedPhase 1Novartis PharmaceuticalsNCT03630159Written as TisagenlecleucelHow we know
Codes
What other systems call tisagenlecleucel · ClinicalTrials.gg INT000899
- MeSH (NLM) C000626284tisagenlecleucelConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) Q6C9WHR03OTISAGENLECLEUCELConfirmed FDA, NLM, Wikidata
- RxNorm 1986438Confirmed FDA, Wikidata
- Wikidata Q30314624tisagenlecleucelConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C102758TisagenlecleucelOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000626284 | tisagenlecleucel | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | Q6C9WHR03O | TISAGENLECLEUCEL | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1986438 | — | Confirmed FDA, Wikidata |
| Wikidata | Q30314624 | tisagenlecleucel | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C102758 | Tisagenlecleucel | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.